WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--ROTATEQ® (rotavirus vaccine, live, oral, pentavalent) reduced rotavirus-related hospitalizations and emergency room (ER) visits combined by 100 percent during the 2007 and 2008 rotavirus seasons (January through May of each year) in an observational study in the United States. The large, national, post-licensure observational study was based on a review of health insurance claims data from approximately 61,000 infants in the U.S. These data on ROTATEQ, the pentavalent rotavirus vaccine from Merck & Co., Inc. that helps prevent rotavirus gastroenteritis in infants and children, were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual Meeting in Washington, D.C.
